Repeating
nature
Medical Additive Manufacturing
Additive Manufacturing is reshaping the field of implantable medical solutions, enhancing resource efficiency while broadening access to quality healthcare for a diverse range of patient needs.
-
Hospitals are increasingly producing standardized and patient-specific implants on-site, enabling localized solutions that improve patient outcomes and healthcare quality.
-
Automated algorithms are transforming implant planning, making it accessible to medical professionals and bridging the gap between technical and clinical domains to support personalized patient care.
True to our name—Additive Manufacturing of Biostable and Bioresorbable Osteoconductive Composite Implants for Osteointegration—Ambrocio is committed to pioneering high-performance, patient-centered solutions in medical additive manufacturing, setting new standards in healthcare.
Medical Additive Manufacturing / Personalized Healthcare / Advanced Solutions / Implantable Medical Devices
Company
Co-founder, CEO
Julia Kulkova,
DDS, PhD, MA, Adjunct Professor in Design and Manufacturing Technologies for Biomedical Implants
“Today, the shift toward patient-centered treatments and implantable solutions is creating unprecedented opportunities for innovation. Positioned at the forefront of healthcare transformation, Ambrocio integrates expertise across every stage—from materials production to clinical application. With cutting-edge technologies and extensive professional knowledge, our team addresses the rising demand for customized implants that elevate patient care.
We envision a future where every medical institution can offer solutions tailored to the unique needs of each patient.”
-
Ambrocio Oy, a privately owned company established in July 2019, was created by a dedicated team of experts in biomedical engineering, clinical science, biomaterials, and industrial design.
Ambrocio specializes in advanced bioactive neurosurgical implants.
Our mission is to advance global health with sustainable solutions, innovative biomaterials, and cutting-edge manufacturing, making transformative healthcare accessible to all.
Technology
Our implants integrate two key components:
Component 1: Polyether-ether-ketone (PEEK)
High durability, proven biocompatibility, and an established clinical track record. Optionally enhanced with calcium phosphate additives (PEEK-BCP) for improved biocompatibility
Component 2: Bioactive Glass S53P4 (BG)
Promotes integration of both hard and soft tissues. FDA-approved for cranio-maxillofacial reconstruction and bone void filling. Demonstrated inhibition of bacterial growth across up to 50 clinically relevant bacterial strains.
Ambrocio Oy holds a unique proprietary technology platform for bone regeneration, forming the core of our implant solutions. This technology is supported by several key patents:
- Finnish Patent FI 126495 B (granted in 2017)
- U.S. Patent US-11382754-B2 (granted in July 2022)
- European Patent EP3370792B1 (granted in April 2020)
Additionally, our advanced Biobuild technology for implant reinforcement using functionalized spatial arrangement of continuous fibers through Additive Manufacturing are protected by:
- Finnish Patent FI 129657 (granted in July 2022)
- U.S. Patent Application US17/626,511 (pending)
- European Patent Application EP20757623.2 (pending)
Contacts
Ambrocio Oy
Business ID: 3012287-7
Werstas, DataCity (Entrance A), Lemminkäisenkatu 14-18 (3rd floor), 20520 Turku, Finland
